Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Journal of Clinical Lipidology

Volumn 10, Issue 4, 2016, Pages 905-914

  Maki, Kevin C ^a   Guyton, John R ^b   Orringer, Carl E ^c   Hamilton Craig, Ian ^d   Alexander, Dominik D ^e   Davidson, Michael H ^f,g  

^a Midwest Center for Metabolic and Cardiovascular Research MB Clinical Research   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d FLINDERS UNIVERSITY   (Australia)

^e EpidStat Institute   (United States)

^f ASTRAZENECA   (United Kingdom)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cardiovascular disease; Cardiovascular events; Fibrates; Hypertriglyceridemia; Lipid altering drug therapy; Niacin; Omega 3 fatty acids; Triglyceride lowering therapy

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID ETHYL ESTER; NICOTINIC ACID; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; META ANALYSIS; METABOLISM; RISK;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; RISK; TRIGLYCERIDES;

EID: 84963984781     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.03.008     Document Type: Article

References (65)

1. 1 Miller, M., Stone, N.J., Ballantyne, C., et al., American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis, and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123 (2011), 2292–2333.
2. 2 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
3. 3 Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 9 (2015), 129–169.
4. 4 Hokanson, J.E., Austin, M.A., Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996), 213–219.
5. 5 Assmann, G., Schulte, H., Funke, H., von Eckardstein, A., The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19:Suppl M (1998), M8–M14.
6. 6 Sarwar, N., Danesh, J., Eiriksdottir, G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 11 (2007), 450–458.
7. 7 Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
8. 8 Sarwar, N., Sandhu, M.S., Ricketts, S.L., et al., Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375 (2010), 1634–1639.
9. 9 Varbo, A., Benn, M., Tybaerg-Hansen, A., Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61 (2013), 427–436.
10. 10 Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Tybjaerg-Hansen, A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371 (2014), 32–41.
11. 11 Nordestgaard, B.G., Varbo, A., Triglycerides and cardiovascular disease. Lancet 384 (2014), 626–635.
12. 12 The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides and coronary disease. N Engl J Med 371 (2014), 22–31.
13. 13 Baigent, C., Keech, A., Kearney, P.M., et al., Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
14. 14 Fruchart, J.C., Sacks, F.M., Hermans, M.P., et al., Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 5 (2008), 319–335.
15. 15 ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
16. 16 Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova, B., Emberson, J., Blackwell, L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
17. 17 Manninen, V., Tenkanen, L., Koskinen, P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992), 37–45.
18. 18 BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102 (2000), 21–27.
19. 19 Yokoyama, M., Origasa, H., Matsuzaki, M., et al., Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
20. 20 Asztalos, B.F., Collins, D., Horvath, K.V., Bloomfield, H.E., Robins, S.J., Schaefer, E.J., Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57 (2008), 77–83.
21. 21 Scott, R., O'Brien, R., Fulcher, G., et al., Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32 (2009), 493–498.
22. 22 AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
23. 23 Mora, S., Wenger, N.K., DeMicco, D.A., et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 125 (2012), 1979–1987.
24. 24 Sasaki, J., Yokoyama, M., Matsuzaki, M., et al., JELIS Investigators. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). J Atheroscler Thromb 19 (2012), 194–204.
25. 25 Maki, K.C., Bays, H.E., Dicklin, M.R., Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 6 (2012), 413–426.
26. 26 Carlson, L.A., Rosenhamer, G., Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988), 405–418.
27. 27 Rubins, H.B., Robins, S.J., Collins, D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999), 410–418.
28. 28 Saito, Y., Yokoyama, M., Origasa, H., et al., JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200 (2008), 135–140.
29. 29 Guyton, J.R., Slee, A.E., Anderson, T., et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 62 (2013), 1580–1584.
30. 30 Davidson, M.H., Rosenson, R.S., Maki, K.C., et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol 34 (2014), 1298–1306.
31. 31 HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
32. 32 Jun, M., Foote, C., Lv, J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010), 1875–1884.
33. 33 Sacks, F.M., Carey, V.J., Fruchart, J.C., Combination lipid therapy in type 2 diabetes. N Engl J Med 363 (2010), 692–694.
34. 34 Lee, M., Saver, J.L., Towfighi, A., Chow, J., Ovbiagele, B., Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 217 (2011), 492–498.
35. 35 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
36. 36 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
37. 37 Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
38. 38 Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
39. 39 The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Eds. Higgins JPT, Green S. Available at: http://www.cochrane.org/handbook. Accessed November 20, 2015.
40. 40 Rothstein, H., Sutton, A., Borenstein, M., Publication Bias in Meta-analysis: Prevention, Assessment, and Adjustments. 2005, John Wiley and Sons, Ltd, Chichester, England.
41. 41 Robins, S.J., Rubins, H.B., Faas, F.H., et al., Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003), 1513–1517.
42. 42 Rubins, H.B., Robins, S.J., Collins, D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veteran Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002), 2597–2604.
43. 43 McLaughlin, T., Reaven, G., Abbasi, F., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol 96 (2005), 399–404.
44. 44 Cui, Y., Blumenthal, R.S., Flaws, J.A., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001), 1413–1419.
45. 45 Liu, J., Sempos, C.T., Donahue, R.P., Dorn, J., Trevisan, M., Grundy, S.M., Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 15 (2006), 1363–1368.
46. 46 Arsenault, B.J., Rana, J.S., Stroes, E.S., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55 (2009), 35–41.
47. 47 Boekholdt, S.M., Arsenault, B.J., Mora, S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307 (2012), 1302–1309.
48. 48 Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol 8 (2014), 29–60.
49. 49 Hourcade-Potelleret, F., Laporte, S., Lehnert, V., et al. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. Heart 101 (2015), 847–853.
50. 50 Kuhnast, S., Fiocco, M., van der Hoorn, J.W., Princen, H.M., Jukema, J.W., Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: a systematic review and meta-analysis of relevant preclinical studies and clinical trials. Eur J Pharmacol 763:Pt A (2015), 48–63.
51. 51 Rosenson, R.S., Brewer, H.B. Jr., Ansell, B.J., et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 13 (2016), 48–60.
52. 52 Szapary, P.O., Rader, D.J., The triglyceride-high-density lipoprotein axis: an important target of therapy?. Am Heart J 148 (2004), 211–221.
53. 53 Tenenbaum, A., Klempfner, R., Fisman, E.Z., Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol, 13, 2014, 159.
54. 54 Welty, F.K., How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?. Curr Cardiol Rep, 15, 2013, 400.
55. 55 Chapman, M.J., Le Goff, W., Guerin, M., Kontush, A., Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31 (2010), 149–164.
56. 56 Stanhope, K.L., Schwarz, J.M., Keim, N.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119 (2009), 1322–1334.
57. 57 Patsch, J.R., Miesenbock, G., Hopferwieser, T., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12 (1992), 1336–1345.
58. 58 Nordestgaard, B.G., Benn, M., Schnohr, P., Tybjaerg-Hansen, A., Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007), 299–308.
59. 59 Rivellese, A.A., Bozzetto, L., Annuzzi, G., Postprandial lipemia, diet, and cardiovascular risk. Curr Cardiovasc Risk Rep 3 (2009), 5–11.
60. 60 Kolovou, G.D., Milhailidis, D.P., Kovar, J., et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9 (2011), 258–270.
61. 61 Boren, J., Matkainen, N., Adiels, M., Taskinen, M.R., Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta 431 (2014), 131–142.
62. 62 Zilversmit, D.B., Atherogenesis: a postprandial phenomenon. Circulation 60 (1979), 473–485.
63. 63 Gower, R.M., Wu, H., Foster, G.A., et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 31 (2011), 160–166.
64. 64 Chan, D.C., Pang, J., Romic, G., Watts, G.F., Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep, 15, 2013, 309.
65. 65 Dechartres, A., Altman, D.G., Trinquart, L., Boutron, I., Ravaud, P., Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 312 (2014), 623–630.